Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
AMGN
AMGN
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
AMGN News
Amgen Stock Rises as Earnings Expectations Draw Attention
2d ago
NASDAQ.COM
Zai Lab Partners with Amgen to Evaluate Lung Cancer Therapy
9h ago
Yahoo Finance
Teva's FDA Approval of Long-Acting Drug Could Be Major Catalyst
1d ago
NASDAQ.COM
Teva Pharmaceutical Shares Surge 130% with Optimistic Outlook
1d ago
Fool
BeOne Medicines Receives Conditional Approval for Lung Cancer Treatment in China
Apr 10 2026
seekingalpha
Analysis of TQQQ ETF's 52-Week Price Fluctuations
Apr 10 2026
NASDAQ.COM
Jim Cramer's Charitable Trust Adjusts Portfolio with J&J and BMY Trades
Apr 08 2026
CNBC
The 'Diabesity' Market Is Poised for Rapid Growth: Key Catalysts for Lilly and Novo Stocks.
Apr 07 2026
Barron's
AMGEN INC: CEO ROBERT A. BRADWAY TO RECEIVE $24.7 MILLION IN TOTAL COMPENSATION FOR 2025, ACCORDING TO SEC FILING
Apr 07 2026
moomoo
Amgen's Phase 3 Trial Success Leads to Viridian Stock Plunge
Apr 06 2026
stocktwits
Viridian Therapeutics Shares Plummet: The Connection to an Amgen Study Explained.
Apr 06 2026
Barron's
Amgen Reports Positive Phase 3 Results for TEPEZZA in Thyroid Eye Disease
Apr 06 2026
NASDAQ.COM
Amgen's Tepezza Treatment Achieves Phase 3 Success
Apr 06 2026
seekingalpha
TEPEZZA OBI Shows Significant Proptosis Reduction in Thyroid Eye Disease Patients
Apr 06 2026
PRnewswire
Amgen's TEPEZZA Phase 3 Trial Shows Promising Results
Apr 06 2026
Newsfilter
Stock Movers: Seagate, Micron, Tesla, Kratos, Strategy, Soleno, Viridian, and Others
Apr 06 2026
Barron's
Show More News
